CD19 and diffuse large B-cell lymphoma: Based on the expectation that multi‐target CAR‐T cell therapeutic strategy should improve efficacy and potentially solve the problem with antigen loss‐associated failure, we treated R/R DLBCL with the combination of anti‐CD19 and anti‐CD20 CAR‐T cells and achieved a promising response with CR rate of 52.4% and ORR rate of 81% albeit the PFS and DOR were not as encouraging.